Abstract. Esophageal cancer (ESCC) is one of the most common causes of cancer-associated mortality in China. The present investigation reveals that non-coding RNAs (ncRNAs), including long ncRNAs (lncRNAs), exert a significant effect on the initiation, development and metastasis of malignant tumors, including ESCC. However, to the best of our knowledge, the function of non-protein-coding genes that host small nucleolar RNAs has not been investigated in cancer, particularly in ESCC. The expression of small nucleolar host gene 6 (SNHG6) in 70 ESCC tissues and paired adjacent tissues was measured by reverse transcription quantitative polymerase chain reaction. Analysis demonstrated that SNHG6 expression was significantly increased in ESCC tissues, and associated with tumor size (P=0.040) and Tumor-Node-Metastasis stage (P<0.01). Knockdown of SNHG6 may inhibit proliferative and colony-forming abilities, and induce apoptosis, in ESCC cells. To the best of our knowledge, the data from the present study indicated for the first time that SNHG6 was upregulated in ESCC tissues and cell lines. This novel lncRNA may exert a marked effect on the generation and progression of ESCC, potentially providing a novel perspective on ESCC diagnosis and management.
Introduction
Esophageal cancer (ESCC) has become one of the leading causes of cancer-associated mortality in China over the past few decades (1) . Despite the marked improvements made in chemotherapy and radiotherapy in the past few decades, metastases and tumor recurrence in ESCC remain associated with a poor prognosis (2) . To improve patient survival, there is a pressing requirement to understand the mechanism of pathogenesis and to identify novel biomarkers and therapeutic targets in patients with ESCC. One potential approach to cancer diagnosis and treatment is through the assessment and targeting of non-coding RNAs (ncRNAs), which are widely transcribed in the eukaryotic genome (2) . Long ncRNAs (lncRNAs), which have become a focus of the study of ncRNAs, are a class of non-coding RNAs characterized by a length of >200 nucleotides (2) . Evidence indicates that lncRNAs may exhibit a marked effect on a number of molecular genetics and cellular processes, including chromatin modification, cellular differentiation and cell cycle regulation (3) . Concurrently, lncRNAs have been demonstrated to be dysregulated in various tumors and to serve as promoters or suppressors in multiple signaling pathways (4) . Previous studies have indicated that lncRNAs are crucial regulators of pathways involved in tumorigenesis and the progression of ESCC, including metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) (5), sprouty RTK signaling antagonist 4-intronic transcript 1 (SPRY4-IT1) (6) and colon cancer-associated transcript 2 (7) . A previous study demonstrated that lncRNA MALAT1 expression was increased in ESCC tissues compared with adjacent normal tissues (5) . MALAT1 knockdown may inhibit ESCC cell proliferation, migration and tumor-sphere formation, but increase cell apoptosis (5) . Downregulation of MALAT1 decreased the expression of β-catenin, Lin28 homolog A and enhancer of zeste 2 polycomb repressive complex 2 subunit (Ezh2), whereas overexpression of Ezh2 reversed the small interfering (si)-MALAT1-mediated repression (5). In addition, Zhang et al (8) identified that the expression of lncRNA SPRY4-IT1 was increased in ESCC cell lines compared with normal esophageal epithelial cells. Overexpression of SPRY4-IT1 may increase ESCC cell motility via induction of the epithelial-mesenchymal transition (8) . On the contrary, other studies also revealed that several lncRNAs may serve as tumor suppressor genes in ESCC, including the lncRNAs low expression in tumor (9) and urothelial cancer associated 1 (10) . However, despite the progress made in understanding lncRNAs, the non-protein-coding genes encoding small nucleolar RNAs (snoRNAs) have received little attention.
snoRNAs, which are ncRNAs, are small RNAs measuring 60-300 nucleotides in length (11) . Owing to their nucleolar localization, the majority of snoRNAs serve as guide RNAs for post-transcriptional modifications, to ensure the production of efficient and accurate ribosomes (12) . It was initially assumed that the non-coding genes encoding snoRNAs have no function, but may host coding sequences in their introns (13) . However, previous studies have indicated that snoRNA host genes (SNHGs) may serve critical roles in cancer, with roles documented for SNHG1 in non-small cell lung cancer (14) , SNHG3 in hepatocellular carcinoma (15) and SNHG12 in human osteosarcoma (16) . A previous study by Makarova and Kramerov (17) proposed the existence of the unusual snoRNA gene small nucleolar host gene 6 (U87HG), also termed SNHG6, which is a housekeeping gene of the 5'-terminal oligopyrimidine tract (TOP) family and associated with ribosomes. SNHG6 demonstrated a high degree of conservation and was ineffectively degraded by nonsense-mediated mRNA decay (NMD), which indicated that it served additional functions separate from the production of U87 RNA (17) . The present study used reverse transcription-quantitative polymerase chain reaction (RT-qPCR), MTT assays, flow cytometry and subcellular fraction assays to investigate the expression and functional roles of lncRNA SNHG6 in ESCC. The results indicated that the expression of SNHG6 was significantly upregulated in ESCC tissues and cell lines compared with normal esophageal epithelial cells. Inhibition of SNHG6 may result in diminished cell growth and increased apoptosis, which indicates the potential role served by SNHG6 in ESCC.
Materials and methods
Tissue samples and patient data. Patients (n=70; age range, 24-84; median age, 64; admitted between January and December 2012) diagnosed with primary ESCC and scheduled for routine surgery at Huai'an First People's Hospital, Nanjing Medical University (Huai'an, China) were included in the present study. All the patients with a histological diagnosis had not received preoperative therapy. Clinical information, including age, gender, history of smoking and drinking, tumor size and pathological Tumor-Node-Metastasis (TNM) stage [according to the 7th AJCC TNM staging system (18)], was collected from clinical data and personal interviews. ESCC and adjacent non-cancerous tissues following resection were snap-frozen in liquid nitrogen and stored at -80˚C. All procedures performed in the present study involving human participants were conducted in accordance with the ethical standards of Huai'an First People's Hospital, Nanjing Medical University and with the 1964 Helsinki declaration and its later amendments. Informed consent was obtained from all individual participants included in the present study.
Cell culture. The ESCC ECA-109 and TE-1 cell lines were purchased from the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in high-glucose Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) containing, penicillin-streptomycin and 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.). A normal human esophageal epithelial cell line (HEEC) was obtained from ScienCell Research Laboratories, Inc. (San Diego, CA, USA) and grown in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.), containing penicillin-streptomycin and 10% FBS. All cells were maintained in humidified incubators under standard conditions (37˚C, 5% CO 2 ).
Cell transfection. ECA-109 and TE-1 cells were transfected with specific small interfering RNA (siRNA) oligonucleotides. A total of 3 different siRNAs (sequences are listed in Table I ) were designed to ensure the efficiency of interference, 2 of which (si-SNHG6-2# and si-SNHG6-3#) were considered appropriate for SNHG6 knockdown as they had an interference efficiency of >70% (Invitrogen; Thermo Fisher Scientific, Inc.). Negative control siRNA (si-NC) was also purchased from Invitrogen; Thermo Fisher Scientific, Inc. ESCC cells were seeded at 6-well plates for 24 h. Cells were then transfected with either SNHG6-siRNA (100 nM) or si-NC (100 nM) using Lipofectamine RNAiMAX transfection reagent ® (Invitrogen; Thermo Fisher Scientific, Inc.), according to the manufacturer's protocol. Following incubation for 48 h, transfected cells were used for further experiments.
RNA extraction and reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis.
Total RNA was extracted from tissues specimens or cultured cells with TRIzol ® reagent (Life Technologies; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. A total of 1 µg total RNA was used for the reverse transcription reaction in a final volume of 20 µl, using random primers from the PrimeScript RT Reagent kit with gDNA Eraser (Takara Biotechnology Co., Ltd., Dalian, China) and 1 µl cDNA was used, according to the manufacturer's protocols, for subsequent RT-qPCR reactions (SYBR Premix Ex Taq, Takara Bio, Inc., Otsu, Japan) of denaturation at 95˚C for 5 sec, annealing at 60˚C for 34 sec, elongation at 68˚C for 20 sec for 40 cycles. The constitutively expression gene GAPDH was used to normalize target gene expression and U1 was used to indicate nuclear expression. The RT-qPCR analysis was performed on ABI 7500 Real-Time PCR system using the 2 -ΔΔCt method (19) (Applied Biosystems; Thermo Fisher Scientific, Inc.). The assay was run in triplicate for each sample. The primer sequences are summarized in Table I . The specimens were divided into a high-expression group (n=50) and a low-expression group (n=20) according to the expression of SNHG6 (a fold-change ≥1 represents high expression of SNHG6, while a fold-change <1 indicates low expression of SNHG6 in ESCC tissues.).
Cell proliferation assays. Each cell line was seeded in flat-bottomed 96-well plates (3,000 cells/well) 24 h following siRNA transfection. The absorbance was measured using a microplate reader at a wavelength of 490 nm. Cell proliferation was evaluated using an MTT Cell Proliferation Reagent kit I (Roche Diagnostics, Basel, Switzerland). For the colony-formation assay, 500 transfected cells were plated in a 6-well plate and maintained in RPMI-1640 containing 10% FBS. After 14 days, cells were washed twice with PBS, then fixed with 4% methanol at room temperature for 15 min and stained with 0.1% crystal violet (dissolved using 95% ethanol) at room temperature for 15 min (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany). The colony formation was determined by counting the number of stained colonies under a light Olympus microscope (x40). All the experiments were performed in triplicate. The formula for the colony formation rate was as follows: Rate (%)=numbers of colony/initial cell population x 100.
Cell apoptosis analysis. Subsequent to transfection with si-SNHG6 or si-NC, cells were harvested using centrifugation (4˚C at 7,500 x g for 5 min) and stained using an Statistical analysis. SPSS 19.0 software (IBM Corp., Armonk, NY, USA) was used to perform statistical analyses. All experiments were performed in triplicate. Student's t-test was performed to evaluate the difference in SNHG6 expression between ESCC and adjacent non-cancerous tissues and was used to compare two independent groups. One-way analysis of variance, followed by a Tukey's post hoc test, was used to compare three or more groups. The association between SNHG6 expression and clinicopathological features was evaluated using Pearson's χ 2 test. P<0.05 was considered to be indicate a statistically significant difference.
Results

SNHG6 is upregulated in ESCC tissues and associated with clinicopathological features.
SNHG6 expression was analyzed in 70 human ESCC specimens and matched non-cancerous tissues by RT-qPCR. The expression level of SNHG6 was significantly increased in ESCC tissues compared with matched adjacent tissues (50 of the 70 tissues, an increase of ≥1.0-fold; P<0.01; Fig. 1A and B) . Subsequently, the specimens were divided into a high-expression group (n=50) and a low-expression group (n=20) according to the expression of SNHG6 (a fold-change ≥1 represents high expression of SNHG6, while a fold-change <1 indicates low expression of SNHG6 in ESCC tissues.). Furthermore, the prognostic role of SNHG6 in determining the clinical significance of patients with ESCC was investigated by analyzing the association between SNHG6 expression and clinicopathological features (Table II) . The data indicated that SNHG6 expression was associated with tumor size (P=0.040) and TNM stage (P<0.01), but was not associated with other parameters.
Effect of SNHG6 on cell proliferation. Since SNHG6 was also upregulated in ESCC ECA109/TE-1 cell lines compared with expression in normal esophageal epithelial HEEC cells (Fig. 1C) , further investigation was undertaken into the functional role of SNHG6 in ESCC. To evaluate the role of SNHG6 in maintaining the malignant phenotypes of ESCC cells, ECA109/TE-1 cells were transfected with si-SNHG6-2# or si-SNHG6-3#, prior to being used for subsequent experiments. The MTT assay demonstrated that the proliferation of ECA109/TE-1 cells was markedly inhibited by the knockdown of SNHG6 ( Fig. 2A and B) . In addition, colony formation assays were performed to assess the effect of SNHG6 on ESCC cells, and indicated that clonogenic survival was markedly decreased following SNHG6 knockdown in ECA109 and TE1 cell lines (Fig. 2C and D) .
Effect of SNHG6 on cell apoptosis. To examine the effect of SNHG6 on cell apoptosis, flow cytometry analysis was utilized. The results of this analysis indicated that the inhibition of SNHG6 markedly induced cell apoptosis compared with the si-NC group (Fig. 2E and F) . Subcellular localization of SNHG6. Following separation of ECA-109 and TE-1 cells, RNA was isolated from the nuclear and cytosolic fractions of the cells and SNHG6 expression was measured by RT-qPCR. GAPDH was used as a reference cytoplasm indicator and U1 was used as a reference nucleus indicator. The results revealed that, in the 2 cell lines, the expression level of SNHG6 was significantly increased in the cytoplasm compared with the nucleus (Fig. 2G and H) .
Discussion
ncRNAs, a class of genetic, epigenetic and translational regulators without protein-coding capacity, contain short and long transcripts and have the potential to be used as biomarkers for multiple diseases (20) . lncRNAs, which are >200 nucleotides, are members of the ncRNA family. It has been demonstrated in a variety of types of cancer that the expression of lncRNAs is closely associated with the carcinogenesis, disease development, metastasis and prognosis of patients with malignancy (4). lncRNAs may become targets for cancer diagnosis and treatment.
A subset of small ncRNAs, snoRNAs, in the nucleoli are involved in multiple steps of rRNA processing (21). According to their structure, snoRNAs may be divided into 2 classes: C/D box snoRNAs, which serve as guide RNAs in site-specific 2'-O-methylation of rRNAs, and H/ACA box snoRNAs, which direct site-specific pseudouridylation of rRNAs (20) . In vertebrates, the majority of snoRNA genes reside within the introns of protein-coding genes and encode nucleolar proteins or proteins involved in translation (22) . However, a small number of SNHGs contain multiple stop codons and do not code for proteins, including UHG (23), U17HG (24), U19HG (25), gas5 (13) and U50HG (26) . In 2005, a study reported the existence of an unusual snoRNA host gene SNHG6, also termed U87HG, a novel lncRNA 472 nucleotides in length and located within an intron of a novel non-protein-coding gene (17) . SNHG6 is a housekeeping gene of the 5'TOP family and is associated with ribosomes. The degree of conservation of SNHG6 RNA is similar to those of the untranslated regions of protein-coding genes. Additionally, SNHG6 RNA is ineffectively degraded by NMD. NMD detects the mRNAs that contain premature termination codons and triggers their degradation to prevent the accumulation of truncated and potentially harmful proteins. Concomitant with the production of U87 RNA, SNHG6 may also participate in translation or its regulation (17) . SNHG6 may be functionally important, owing to the areas of high local similarity to U87 RNA interspersed among the loosely-conserved sequence it contains (17) .
In the present study, the function of SNHG6 in ESCC, and the potential association between its expression and Table II . Association between SNHG6 expression and clinicopathological characteristics in esophageal squamous cell carcinoma. clinicopathological features was examined. Data analysis indicated that the upregulation of SNHG6 was associated with tumor size and TNM stage. The expression level of SNHG6 in ECA109 and TE-1 cells was significantly increased compared with that in HEEC cells. Induced downregulation of SNHG6 markedly inhibited the proliferative and colony-forming abilities of, and induced apoptosis in, ESCC cells, indicating its oncogenic role. This result indicated the critical role of SNHG6 in tumorigenesis and the progression of ESCC. Additional experimental results demonstrated that SNHG6 RNA was predominately localized in the cytoplasm, which was consistent with data from Makarova and Kramerov (17) . As it appears that the regulatory mechanisms of lncRNAs are usually associated with their localization (4), it can be assumed that SNHG6 may serve as a microRNA sponge, which are able to bind with several miRNAs to inhibit their expression and their downstream pathways, or as an RNA-binding protein to regulate the expression of target genes and participate in multiple pathways, contributing to its oncogenic role in ESCC. Chaudhry (27) suggested that SNHG6 may be involved in the ionizing radiation (IR)-induced stress response in a tumor protein p53 (p53)-dependent manner. Similarly, a previous study indicated that sno-microRNA-28, which directly targets the p53-stabilizing gene TATA-box binding protein associated factor 9b, was transcriptionally repressed by p53 through SNHG1 (28) . These molecules form a regulatory loop that affects p53 stability and downstream p53-regulated pathways (28) . Furthermore, Zhao et al (29) identified that SNHG5 may affect acetylation by trapping metastasis-associated 1 family member 2 in the cytosol. SNHG5 overexpression may significantly increase the acetylation levels of histone H3 and p53, thereby interfering with the formation of the nucleosome remodeling and histone deacetylation complex (29) . Therefore, it is possible that SNHG6 may also affect the cell cycle and apoptosis through p53-associated pathways.
In conclusion, the present study revealed that SNHG6 may exhibit an important effect on the oncogenesis and development of ESCC. As a potential predictor and a promising alternative therapeutic target for future ESCC treatment, the detailed molecular mechanism of SNHG6 involved in ESCC should be clarified by additional studies.
